FDA Regulatory Pathways for Medical Devices: 510(k), De Novo & PMA
Bringing a new medical device to the U.S. market requires manufacturers to select the appropriate FDA regulatory pathway before preparing a submission.
The correct pathway depends on several factors, including the device’s intended use, indications for use, technological characteristics, risk profile, classification, and whether a suitable legally marketed predicate exists.
The three major pathways manufacturers commonly evaluate are 510(k), De Novo, and Premarket Approval (PMA). However, not every device requires one of these submissions. Some Class I and Class II devices are exempt from 510(k), subject to applicable limitations.
Understanding these pathways early can help manufacturers avoid preparing the wrong type of submission and collecting evidence that does not align with FDA expectations.
Talk to our Experts
What Are the Main FDA Regulatory Pathways for Medical Devices?
The main regulatory pathways for medical devices can be summarized as follows:
FDA pathway | Typical situation | Main regulatory concept |
510(k) | Suitable predicate exists | Substantial equivalence |
De Novo | Novel device with no suitable predicate and appropriate risk profile | New classification |
PMA | Most high-risk Class III devices | Reasonable assurance of safety and effectiveness |
HDE | Certain devices for rare diseases/conditions | Humanitarian-use pathway |
FDA describes 510(k) as a pathway for eligible Class I and II devices that are not exempt, De Novo for novel low-to-moderate-risk devices without a suitable predicate, and PMA for Class III devices.
How Do You Determine the Correct FDA Pathway?
The first step is not choosing between 510(k), De Novo, and PMA. It is determining how FDA classifies the device.
FDA assigns medical devices to Class I, Class II, or Class III, based on the level of regulatory control needed to provide reasonable assurance of safety and effectiveness. Class I has the lowest level of regulatory control, while Class III has the highest.
Manufacturers should evaluate:
- Intended use
- Indications for use
- Device technology
- Risk profile
- Applicable classification regulation
- Product code
- Predicate availability
- Clinical and performance evidence requirements
This assessment determines which FDA regulatory pathway is potentially appropriate.
1. 510(k) Regulatory Pathway
The 510(k) regulatory pathway is used when a manufacturer can demonstrate that its device is substantially equivalent to a legally marketed predicate device.
The new device does not necessarily need to be identical to the predicate. FDA evaluates whether differences in intended use, technology, performance, and other characteristics raise different questions of safety and effectiveness.
A typical 510(k) strategy involves:
- Identifying an appropriate predicate.
- Defining the intended use and indications.
- Comparing technological characteristics.
- Establishing substantial equivalence.
- Conducting applicable performance testing.
- Preparing labeling and other required documentation.
- Submitting the 510(k) to FDA.
FDA currently provides three 510(k) submission programs: Traditional, Special, and Abbreviated 510(k), when the applicable eligibility conditions are met.
When Is 510(k) Appropriate?
A 510(k) may be appropriate when:
- A suitable legally marketed predicate exists.
- The device is subject to 510(k) requirements.
- The new device has the same intended use as the predicate.
- Technological differences do not raise different questions of safety and effectiveness, or those differences can otherwise be adequately addressed.
Not every Class II device automatically requires a 510(k), because some devices are exempt subject to limitations.
2. De Novo Regulatory Pathway
What happens when there is no suitable predicate device?
This is where the De Novo pathway can become relevant.
De Novo is intended for certain novel devices that do not have a legally marketed predicate but are considered sufficiently low to moderate risk to be appropriately regulated through general controls alone or general and special controls.
If FDA grants a De Novo request, the device receives a new classification. The resulting classification can also establish a regulatory basis for future devices that are substantially equivalent to the newly classified device.
When Should Manufacturers Consider De Novo?
A manufacturer may evaluate De Novo when:
- No suitable predicate exists.
- The device is novel.
- The device presents a low-to-moderate risk profile appropriate for De Novo classification.
- General controls or general and special controls can provide reasonable assurance of safety and effectiveness.
Therefore, “no predicate” does not automatically mean PMA.
Schedule a Compliance Consultation
Accelerate Market Access with End-to-End Regulatory Guidance
3. Premarket Approval (PMA)
Premarket Approval (PMA) is FDA’s rigorous pathway for demonstrating the safety and effectiveness of applicable high-risk devices.
Most Class III devices require PMA unless another regulatory provision applies. FDA describes PMA as the pathway for Class III devices, which are subject to the highest level of regulatory controls.
A PMA submission can require substantial evidence addressing:
- Device design
- Manufacturing information
- Nonclinical testing
- Clinical data
- Risk-benefit considerations
- Labeling
- Manufacturing controls
- Safety and effectiveness
Because the evidentiary burden can be significant, manufacturers should establish the regulatory and clinical strategy early in product development.
510(k) vs De Novo vs PMA
Factor | 510(k) | De Novo | PMA |
Predicate | Generally required | Not required | Not the basis of the pathway |
Typical risk | Low-to-moderate | Low-to-moderate | High |
Main objective | Demonstrate substantial equivalence | Establish new classification | Demonstrate safety and effectiveness |
Clinical evidence | Depends on device | May be required | Often significant |
Regulatory burden | Moderate | Moderate | High |
Typical use | Existing device types | Novel device types | High-risk devices |
The table provides a strategic overview; the actual evidence and submission requirements depend on the specific device and FDA requirements.
How Operon Strategist Helps With FDA Regulatory Pathways
Selecting the correct FDA regulatory pathway for medical devices is an important strategic decision. Operon Strategist supports manufacturers with regulatory planning before submission, helping align the device’s intended use, classification, predicate strategy, evidence requirements, and FDA submission pathway.
Our support can include:
- FDA regulatory pathway assessment
- Device classification
- Predicate device research
- 510(k) strategy and preparation
- De Novo regulatory strategy
- PMA regulatory support
- Pre-Submission preparation
- Technical documentation
- Clinical and performance evidence strategy
- FDA submission support
The objective is to establish the right regulatory strategy early and reduce avoidable delays during the submission process.
Key Takeaways
- FDA medical devices are classified as Class I, II, or III based on risk and required regulatory controls.
- A suitable predicate can support a 510(k) pathway.
- A novel low-to-moderate-risk device without a suitable predicate may be considered for De Novo.
- Most applicable high-risk Class III devices require PMA.
- Some Class I and Class II devices are exempt from 510(k), subject to applicable limitations.
- A Pre-Submission can help manufacturers obtain FDA feedback before committing to a major submission strategy.
- The correct pathway should be determined early in product development.
Ensure Seamless Regulatory Compliance for Your Device
Get Your Medical Device Market-Ready with Expert Regulatory Support
FAQ's
What are the main FDA regulatory pathways for medical devices?
The major pathways include 510(k) premarket notification, De Novo classification, and Premarket Approval (PMA). Certain devices may also qualify for exemptions or specialized pathways such as HDE.
What is the 510(k) regulatory pathway?
The 510(k) pathway is used to demonstrate that a new device is substantially equivalent to a legally marketed predicate device. FDA clearance allows an eligible device to be marketed in the United States.
Can a medical device receive FDA clearance without a predicate?
Yes. A novel low-to-moderate-risk device without a suitable predicate may potentially use the De Novo pathway. If granted, De Novo establishes a new classification for the device.
Is PMA required for every Class III medical device?
Most Class III devices require PMA, but specific regulatory provisions can affect the applicable pathway. Manufacturers should verify the device’s classification and applicable FDA requirements before selecting a submission type.
What determines the FDA classification of a medical device?
FDA classification depends primarily on the device’s intended use, indications for use, technology, and risk. FDA assigns devices to Class I, II, or III according to the regulatory controls necessary to provide reasonable assurance of safety and effectiveness.